Par Pharmaceutical Companies Q2 FY15: revenue $332.2M, up 12%

Key figures from this report

These are the numbers Par Pharmaceutical Companies reported for Q2 FY15, the quarter ended Jun 30, 2015, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

1. Revenue$332.2M+12% from $295.4M in Q2 FY1410-Q income statement, on EDGAR
2. Net income$5.4MAgainst −$26.9M in Q2 FY1410-Q income statement, on EDGAR
3. Cash and cash equivalents$154.9M−1% from $155.9M in Q2 FY1410-Q balance sheet, on EDGAR
4. Cash from operations$432KAgainst −$61.6M in Q2 FY1410-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters